Please login to the form below

Not currently logged in
Email:
Password:

chronic heart failure

This page shows the latest chronic heart failure news and features for those working in and with pharma, biotech and healthcare.

AZ claims first-in-class win for Farxiga in heart failure

AZ claims first-in-class win for Farxiga in heart failure

AZ in pursuit of class leader Jardiance. AstraZeneca has moved a step close to a chronic heart failure claim for its diabetes drug Farxiga after reporting positive results in a phase ... a heart failure claim for Farxiga in diabetic and non-diabetic HFrEF

Latest news

  • Boehringer posts solid first half as business revamp beds in Boehringer posts solid first half as business revamp beds in

    Boehringer said in its interim results statement that it is anticipating further upward momentum if it can claim an approval  for the SGLT2 inhibitor for people with chronic heart failure, with ... Meanwhile, Boehringer is also testing the impact of

  • FDA fast-tracks Jardiance for heart failure review FDA fast-tracks Jardiance for heart failure review

    These studies look at empagliflozin’s impact on cardiovascular death and hospitalisation for heart failure in adults with chronic heart failure with reduced or preserved ejection fraction, respectively. ... Boehringer Ingelheim and Lilly are committed

  • Amgen, Servier heart failure drug clears trial hurdle Amgen, Servier heart failure drug clears trial hurdle

    Amgen and Servier have inched closer to a verdict on their first-in-class chronic heart failure drug omecamtiv mecarbil, after their first phase 3 study passed a futility review. ... It is one of a handful of new drugs in late-stage development for

  • Amgen, Servier start second phase 3 trial of heart failure hope Amgen, Servier start second phase 3 trial of heart failure hope

    Exercise intolerance, typically manifested by shortness of breath and fatigue on exertion, is a predominant symptom of chronic heart failure and often the first symptom that prompts patients to seek medical ... One advance in drug treatment was the

  • Astellas makes another gene therapy play with Juventas deal Astellas makes another gene therapy play with Juventas deal

    The choice of lead indication for JVS-100 is an interesting one, given that the therapy also has potential in other, more life-threatening indications such as chronic heart failure (CHF)

More from news
Approximately 4 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • A healthy challenge A healthy challenge

    Chronic diseases. One of the standout findings of the Health at a Glance report concerned the impact of chronic diseases in Europe. ... All told, 50 million people in the EU are afflicted by conditions such as diabetes, congestive heart failure, chronic

  • Pharma deals during July 2013 Pharma deals during July 2013

    Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates. ... Omecamtiv mecarbil is currently in phase II trials

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Enablers of drug innovation could lie in the numbers

    As drugs become more and more targeted, the need for this data is compounded, and information such as the whereabouts of the greatest concentration of patients with chronic heart failure, and ... a reduced ejection fraction within the New York Heart

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics